REFERENCES

AFI (American Film Institute). 2003. AFI’s 100 years … 100 heroes & villains. http://www.afi.com/100years/handv.aspx (accessed November 7, 2012).

AMA (American Medical Association). 2012. About us. http://www.ama-assn.org/ama/pub/physician-resources/medical-science/united-states-adopted-names-council/about-us.page? (accessed November 16, 2012).

American Heritage Stedman’s Medical Dictionary. 2012a. “Drug.” Boston, MA: Houghton Mifflin.

———. 2012b. “Medicine.” Boston, MA: Houghton Mifflin.

———. 2012c. “Pharmaceutical.” Boston, MA: Houghton Mifflin.

Amin, A., and R. Snow. 2005. Brands, costs and registration status of antimalarial drugs in the Kenyan retail sector. Malaria Journal 4(36). DOI: 10.1186/1475-2875-4-36.

Anvisa. 2006. The Anvisa effort on combating counterfeit medicines in Brazil. Paper presented at World Congress of Pharmacy and Pharmaceutical Sciences 2006: 66th International Congress of FIP, Salvador Bahia, Brazil.

Attaran, A., D. Barry, S. Basheer, R. Bate, D. Benton, J. Chauvin, L. Garrett, I. Kickbusch, J. C. Kohler, K. Midha, P. N. Newton, S. Nishtar, P. Orhii, and M. McKee. 2012. How to achieve international action on falsified and substandard medicines. British Medical Journal 345. DOI: 10.1136/bmj.e7381.

Attaran, A., and R. Bate. 2010. A counterfeit drug treaty: Great idea, wrong implementation. Lancet 376(July):1446-1448.

AVMA (American Veterinary Medical Association). 2012. Representation to the United States Pharmacopeial Convention (USP). https://www.avma.org/KB/Policies/Pages/Representation-to-the-United-States-Pharmacopeial-Convention-USP.aspx (accessed Novemeber 19, 2012).

Barton, J. H. 2004. TRIPS and the global pharmaceutical market. Health Affairs 23(3):146-154.

Bate, R. 2010. Lessons from a Syrian drug bust. Wall Street Journal, April 28.

———. 2011. The market for inferior medicines: Comparing the price of falsified and substandard poducts with the legitimate medicines in emerging markets. Washington, DC: American Enterprise Institute.

———. 2012a. The deadly world of falsified and substandard medicine. http://www.aei.org/article/health/global-health/the-deadly-world-of-falsified-and-sub-standard-medicine (accessed November 9, 2012).

———. 2012b (March 13). Defining dangerous drugs. Presentation at Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products: Meeting One, Institute of Medicine, Washington, DC.

BBC (British Broadcasting Corporation). 2001a. Court battle over AIDS drugs. BBC News, March 5.

———. 2001b. SA victory in AIDS drugs case. BBC News, April 19.

Beebe, B. 2006. An empirical study of the multifactor tests for trademark infringement. California Law Review 94:1581-1654.

Björkman-Nyqvist, M., J. Svensson, and D. Yanagizawa-Drott. 2012. Can good products drive out bad? Evidence from local markets for (fake?) antimalarial medicine in Uganda. Cambridge, MA: Harvard University Center for International Development.

Brant, J., and R. Malpani. 2011. Eye on the ball medicine regulation—not IP enforcement—can best deliver quality medicines. Oxford, UK: Oxfam International.

Bren, L. 2001. Frances Oldham Kelsey: FDA medical reviewer leaves her mark on history. FDA Consumer Magazine 35(2):24-29.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement